Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | PRKCI | P41743 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253223 | 0.89 | NPC1 (0.61) | BAZ2BMAOAMAOBPRKCINPC1 | |
| SCHEMBL18159338 | 0.86 | NPC1 (0.53) | BAZ2BMAOAMAOBPRKCINPC1 | |
| SCHEMBL29546005 | 0.84 | ALDH1A1 (0.65) | BAZ2BMAOAMAOBPRKCIMAPT | |
| SCHEMBL356493 | 0.84 | ALDH1A1 (0.65) | BAZ2BMAOAMAOBPRKCIMAPT | |
| SCHEMBL9944562 | 0.83 | MAOA (0.59) | BAZ2BMAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL10436091 | 0.83 | MAOA (0.59) | BAZ2BMAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL1090221 | 0.83 | MAOA (0.59) | BAZ2BMAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL30853876 | 0.83 | MAOA (0.59) | BAZ2BMAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL19029127 | 0.82 | BAZ2B (0.56) | BAZ2BMAOAMAOBPRKCIMAPT | |
| SCHEMBL353895 | 0.82 | BAZ2B (0.56) | BAZ2BMAOAMAOBPRKCINPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299169-B | Synthesis method of 6-chloro-3, 4-dihydro-2H-1-naphthalenone | 南京杰运医药科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| WO-2011018170-A2 | PESTICIDAL CARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | BAZ2B 908/4885MAOA 469/4885MAOB 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.